|

EB-DTKN-401 allogeneic dual-target CSPG4/GD2 CAR-NK cells Clinical Trials

1 actively recruiting trial

Pipeline

Phase 1/2: 1

Top Sponsors

  • Beijing Biotech1

Indications

  • Metastatic Cutaneous Melanoma1
  • Metastatic Uveal Melanoma1
  • Unresectable Melanoma1
  • Cancer1

Other1 trial

Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.